<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247428</url>
  </required_header>
  <id_info>
    <org_study_id>MIS-FIH-2010-01</org_study_id>
    <nct_id>NCT01247428</nct_id>
  </id_info>
  <brief_title>First-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease</brief_title>
  <acronym>DESSOLVE-I</acronym>
  <official_title>A First-In-Human Trial of a New Novel DES (MiStent System) With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesions in the Native Coronary Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Micell Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Micell Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DESSOLVE I clinical trial is to assess the safety and performance of the
      sirolimus-eluting MiStent SES.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DESSOLVE I clinical trial is to assess the safety and performance of the
      sirolimus-eluting MiStent for the treatment for improving coronary luminal diameter in
      patients with symptomatic ischemic heart disease due to discrete de novo lesions &lt; 20 mm in
      length in the native coronary arteries with reference vessel diameters between 2.5 mm and 3.5
      mm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic In-Stent Late Lumen Loss</measure>
    <time_frame>8 months</time_frame>
    <description>In-stent late lumen loss as measured by the angiographic core laboratory as the difference between the post-procedure minimal lumen diameters (MLD) in the treated segment (stented region) minus the MLD in the same region at follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>240 days</time_frame>
    <description>Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q-wave and non-Q-wave) and target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>8 hours</time_frame>
    <description>Achievement of a final in-stent residual diameter stenosis of &lt;50% (by QCA), using the assigned device only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Success</measure>
    <time_frame>8 hours</time_frame>
    <description>Achievement of a final in-stent residual diameter stenosis of &lt;50% (by QCA) using any percutaneous method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>8 hours</time_frame>
    <description>Achievement of a final in-stent residual diameter stenosis of &lt;50% (by QCA) using the assigned device (including any adjunctive devices) without cardiac death, Myocardial infarction (MI) or repeat revascularization of the target lesion pre-hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Mortality</measure>
    <time_frame>240 days</time_frame>
    <description>Total mortality (cardiac and non-cardiac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Myocardial Infarction (MI)</measure>
    <time_frame>240 days</time_frame>
    <description>Q-wave MI (QWMI): requires one of the following criteria: the development of new abnormal Q waves in ≥2 contiguous ECG leads not present on the patient's baseline (i.e., before intervention) in association with a &gt;2x upper limit normal elevation of creatine kinase (CK) levels. In the absence of ECG data, the clinical events committee may adjudicate a Q-wave MI based on the clinical scenario and appropriate cardiac enzyme data; chest pain or other acute symptoms consistent with myocardial ischemia and new pathological Q waves in ≥2 contiguous ECG leads in the absence of timely cardiac enzyme data.
Non-Q-wave MI (NQWMI): the elevation of CK levels (≥2 times ULN) with elevated CK-MB enzyme levels in the absence of new pathologic Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven Target Lesion Revascularization (TLR) Rates</measure>
    <time_frame>240 days</time_frame>
    <description>A revascularization is considered clinically driven if angiography at follow-up shows a percent diameter stenosis ≥ 50% (Angiographic Core Laboratory QCA assessment) and if one of the following occurs:
A positive history of recurrent angina pectoris, presumably related to the target vessel;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);
A target lesion revascularization (TLR) with a diameter stenosis ≥ 70% even in the absence of the above-mentioned ischemic signs or symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven Target Vessel Revascularization (TVR) Rates</measure>
    <time_frame>240 days</time_frame>
    <description>A revascularization is considered clinically driven if angiography at follow-up shows a percent diameter stenosis ≥ 50% (Angiographic Core Laboratory QCA assessment) and if one of the following occurs:
A positive history of recurrent angina pectoris, presumably related to the target vessel;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);
A target vessel revascularization (TVR) with a diameter stenosis ≥ 70% even in the absence of the above-mentioned ischemic signs or symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>240 days</time_frame>
    <description>Target vessel failure (TVF) is defined as the composite endpoint of:
cardiac death,
target-vessel myocardial infarction (Q wave or non-Q wave), and
clinically indicated target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>240 days</time_frame>
    <description>Target lesion failure (TLF) is defined as the composite endpoint of:
cardiac death,
target-lesion myocardial infarction (Q wave or non-Q wave), and
clinically indicated target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>240 days</time_frame>
    <description>The presence of an intracoronary thrombus that originates in the stent or in the segments 5 mm proximal or distal to the stent post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Evaluation: In-stent Binary Restenosis</measure>
    <time_frame>4 months, 6 months, 8 months</time_frame>
    <description>Binary Restenosis is defined as ≥50% luminal narrowing at follow-up angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Evaluation: In-stent Binary Restenosis</measure>
    <time_frame>18 months</time_frame>
    <description>Binary Restenosis is defined as ≥50% luminal narrowing at follow-up angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intravascular Ultrasound (IVUS) Evaluation: % Neointimal Volume Obstruction</measure>
    <time_frame>8 months</time_frame>
    <description>% neointimal volume obstruction is defined as the neointimal volume divided by stent volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS Evaluation: % Neointimal Volume Obstruction</measure>
    <time_frame>18 months</time_frame>
    <description>% neointimal volume obstruction is defined as the neointimal volume divided by stent volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical Coherence Tomography (OCT) Evaluation: % Stent Strut Uncovered</measure>
    <time_frame>8 months</time_frame>
    <description>% stent strut uncovered is defined as the ratio of uncovered struts to total struts in all cross-sections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OCT Evaluation: % Stent Strut Uncovered</measure>
    <time_frame>18 M</time_frame>
    <description>% stent strut uncovered is defined as the ratio of uncovered struts to total struts in all cross-sections.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>MiStent SES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MiStent SES</intervention_name>
    <description>The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
    <arm_group_label>MiStent SES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male/female patients 18-85 years;

          2. Stable or unstable angina pectoris, ischemia, or silent ischemia;

          3. Planned single, de novo, types A, B1 and B2 coronary lesions;

          4. Target lesion located in a native coronary artery;

          5. Target lesion vessel diameter 2.5 to 3.5 mm amenable to treatment with a maximum 23 mm
             long stent;

          6. Target lesion &gt;50% diameter stenosis;

          7. Patients eligible for percutaneous coronary intervention (PCI);

          8. Acceptable candidate for myocardial revascularization surgery;

          9. A patient may have one additional critical non-target lesion.

         10. The patient will provide written informed consent.

        Exclusion Criteria:

          1. Female of childbearing potential not on some form of birth control with a confirmed
             negative pregnancy test at baseline;

          2. Recent Q-wave myocardial infarction occurred &lt;72 hours prior to the index procedure.
             Recent myocardial infarction with elevated levels of cardiac markers;

          3. Left ventricular ejection fraction &lt;30%;

          4. Patients in cardiogenic shock;

          5. Cerebrovascular accident or transient ischemic attack within 6 months;

          6. Active GI bleed within three months;

          7. Any prior true anaphylactic reaction to contrast agents;

          8. Patient receiving/scheduled to receive chemotherapy within 30-days before or after the
             index procedure;

          9. Patient is receiving immunosuppressive therapy or has known life-limiting
             immunosuppressive/autoimmune disease;

         10. Renal dysfunction (creatinine &gt; 2.0 mg/dL or 177 µmol/L);

         11. Platelet count &lt;100,000 cells/mm³ or &gt;700,000 cells/mm³;

         12. White blood cell count &lt;3,000 cells/mm3;

         13. Hepatic disease;

         14. Heart transplant recipient;

         15. Known contraindication to dual antiplatelet therapy;

         16. Known hypersensitivity to sirolimus, cobalt-chromium, or to medications such as
             aspirin, heparin, and all three of the following: clopidogrel bisulfate (Plavix),
             ticlopidine (Ticlid), and Prasugrel (Effient);

         17. Life expectancy &lt;12 months;

         18. Any major medical condition that may interfere with the optimal participation of the
             patient in this study;

         19. Patient is currently participating/planning to participate in an investigational drug
             or another device study prior to completing 12-months follow-up;

         20. Target vessel(s) has been treated within 10 mm proximal or distal to target lesion
             with any type of PCI within a year prior to index procedure;

         21. Planned or actual target vessel(s) treatment with an unapproved device, directional or
             rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction
             catheter prior to stent placement;

         22. Previous coronary intravascular brachytherapy;

         23. Planned coronary angioplasty or coronary artery bypass grafting (CABG)in the first 9
             months after the index procedure;

         24. Prior PCI of a non-target vessel must be at least 30 days prior to study enrollment;

         25. The intent to direct stent the target lesion;

         26. Angiographic Exclusion Criteria: Assessed prior to stent placement;

               -  In-stent restenotic target lesion;

               -  More than one lesion requiring treatment in the target vessel;

               -  Target vessel diameter &lt;2.5 mm or &gt;3.5 mm;

               -  Target lesion not amenable to treatment with a 23 mm long stent;

               -  Unprotected coronary artery branch lesion (≥50% DS);

               -  Target lesion located in a surgical bypass graft;

               -  Total vessel occlusion;

               -  Target lesion with ostial location;

               -  Target lesion located in a lateral branch bifurcation &gt;2.5mm or requiring lateral
                  branch stenting;

               -  Calcified target lesion that anticipates unsuccessful/impracticable predilation;

               -  Target vessel excessive tortuosity or proximal angulation (&gt;90 degrees);

               -  Thrombus present in target vessel;

               -  More than one non-target critical lesion;

        Non-target lesion to be treated during the index procedure meets any of the following
        criteria:

          -  Within the target vessel;

          -  Within a bypass graft;

          -  Left main location;

          -  Chronic total occlusion;

          -  Involves a complex bifurcation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Wijns, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Center, Onze-Lieve-Vrouwziekenhuis Aalst (OLV Hospital)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Ormiston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Angiography Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent's Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwziekenhuis Aalst (OLV Hospital)</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1032</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Angiography Unit - Mercy Hospital</name>
      <address>
        <city>Aukland</city>
        <zip>1032</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>New Zealand</country>
  </location_countries>
  <results_reference>
    <citation>Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries). JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013. Epub 2013 Sep 18.</citation>
    <PMID>24055443</PMID>
  </results_reference>
  <results_reference>
    <citation>Attizzani GF, Bezerra HG, Ormiston J, Wang W, Donohoe D, Wijns W, Costa MA. Serial assessment by optical coherence tomography of early and late vascular responses after implantation of an absorbable-coating Sirolimus-Eluting stent (from the first-in-human DESSOLVE I trial). Am J Cardiol. 2013 Nov 15;112(10):1557-64. doi: 10.1016/j.amjcard.2013.07.013. Epub 2013 Aug 29.</citation>
    <PMID>23992957</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <results_first_submitted>December 19, 2013</results_first_submitted>
  <results_first_submitted_qc>June 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 12, 2014</results_first_posted>
  <last_update_submitted>December 15, 2016</last_update_submitted>
  <last_update_submitted_qc>December 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Drug-eluting Stent</keyword>
  <keyword>Sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MiStent SES</title>
          <description>The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with symptomatic ischemic heart disease due to discrete de novo lesions &lt; 20 mm in length in the native coronary arteries with reference vessel diameters between 2.5 mm and 3.5 mm.</population>
      <group_list>
        <group group_id="B1">
          <title>MiStent SES</title>
          <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.6" spread="9.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Angiographic In-Stent Late Lumen Loss</title>
        <description>In-stent late lumen loss as measured by the angiographic core laboratory as the difference between the post-procedure minimal lumen diameters (MLD) in the treated segment (stented region) minus the MLD in the same region at follow-up.</description>
        <time_frame>8 months</time_frame>
        <population>Last observation used, such that patients (n=10) in the 8 month analysis is reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic In-Stent Late Lumen Loss</title>
          <description>In-stent late lumen loss as measured by the angiographic core laboratory as the difference between the post-procedure minimal lumen diameters (MLD) in the treated segment (stented region) minus the MLD in the same region at follow-up.</description>
          <population>Last observation used, such that patients (n=10) in the 8 month analysis is reported.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Major Adverse Cardiac Events (MACE)</title>
        <description>Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q-wave and non-Q-wave) and target vessel revascularization (TVR)</description>
        <time_frame>240 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Major Adverse Cardiac Events (MACE)</title>
          <description>Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q-wave and non-Q-wave) and target vessel revascularization (TVR)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Success</title>
        <description>Achievement of a final in-stent residual diameter stenosis of &lt;50% (by QCA), using the assigned device only</description>
        <time_frame>8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success</title>
          <description>Achievement of a final in-stent residual diameter stenosis of &lt;50% (by QCA), using the assigned device only</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.67" lower_limit="82.78" upper_limit="99.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Success</title>
        <description>Achievement of a final in-stent residual diameter stenosis of &lt;50% (by QCA) using any percutaneous method</description>
        <time_frame>8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Success</title>
          <description>Achievement of a final in-stent residual diameter stenosis of &lt;50% (by QCA) using any percutaneous method</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="88.43" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>Achievement of a final in-stent residual diameter stenosis of &lt;50% (by QCA) using the assigned device (including any adjunctive devices) without cardiac death, Myocardial infarction (MI) or repeat revascularization of the target lesion pre-hospital discharge</description>
        <time_frame>8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Achievement of a final in-stent residual diameter stenosis of &lt;50% (by QCA) using the assigned device (including any adjunctive devices) without cardiac death, Myocardial infarction (MI) or repeat revascularization of the target lesion pre-hospital discharge</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="88.43" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Mortality</title>
        <description>Total mortality (cardiac and non-cardiac)</description>
        <time_frame>240 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Total Mortality</title>
          <description>Total mortality (cardiac and non-cardiac)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Myocardial Infarction (MI)</title>
        <description>Q-wave MI (QWMI): requires one of the following criteria: the development of new abnormal Q waves in ≥2 contiguous ECG leads not present on the patient's baseline (i.e., before intervention) in association with a &gt;2x upper limit normal elevation of creatine kinase (CK) levels. In the absence of ECG data, the clinical events committee may adjudicate a Q-wave MI based on the clinical scenario and appropriate cardiac enzyme data; chest pain or other acute symptoms consistent with myocardial ischemia and new pathological Q waves in ≥2 contiguous ECG leads in the absence of timely cardiac enzyme data.
Non-Q-wave MI (NQWMI): the elevation of CK levels (≥2 times ULN) with elevated CK-MB enzyme levels in the absence of new pathologic Q waves.</description>
        <time_frame>240 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Total Myocardial Infarction (MI)</title>
          <description>Q-wave MI (QWMI): requires one of the following criteria: the development of new abnormal Q waves in ≥2 contiguous ECG leads not present on the patient's baseline (i.e., before intervention) in association with a &gt;2x upper limit normal elevation of creatine kinase (CK) levels. In the absence of ECG data, the clinical events committee may adjudicate a Q-wave MI based on the clinical scenario and appropriate cardiac enzyme data; chest pain or other acute symptoms consistent with myocardial ischemia and new pathological Q waves in ≥2 contiguous ECG leads in the absence of timely cardiac enzyme data.
Non-Q-wave MI (NQWMI): the elevation of CK levels (≥2 times ULN) with elevated CK-MB enzyme levels in the absence of new pathologic Q waves.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically-driven Target Lesion Revascularization (TLR) Rates</title>
        <description>A revascularization is considered clinically driven if angiography at follow-up shows a percent diameter stenosis ≥ 50% (Angiographic Core Laboratory QCA assessment) and if one of the following occurs:
A positive history of recurrent angina pectoris, presumably related to the target vessel;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);
A target lesion revascularization (TLR) with a diameter stenosis ≥ 70% even in the absence of the above-mentioned ischemic signs or symptoms.</description>
        <time_frame>240 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically-driven Target Lesion Revascularization (TLR) Rates</title>
          <description>A revascularization is considered clinically driven if angiography at follow-up shows a percent diameter stenosis ≥ 50% (Angiographic Core Laboratory QCA assessment) and if one of the following occurs:
A positive history of recurrent angina pectoris, presumably related to the target vessel;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);
A target lesion revascularization (TLR) with a diameter stenosis ≥ 70% even in the absence of the above-mentioned ischemic signs or symptoms.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically-driven Target Vessel Revascularization (TVR) Rates</title>
        <description>A revascularization is considered clinically driven if angiography at follow-up shows a percent diameter stenosis ≥ 50% (Angiographic Core Laboratory QCA assessment) and if one of the following occurs:
A positive history of recurrent angina pectoris, presumably related to the target vessel;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);
A target vessel revascularization (TVR) with a diameter stenosis ≥ 70% even in the absence of the above-mentioned ischemic signs or symptoms.</description>
        <time_frame>240 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically-driven Target Vessel Revascularization (TVR) Rates</title>
          <description>A revascularization is considered clinically driven if angiography at follow-up shows a percent diameter stenosis ≥ 50% (Angiographic Core Laboratory QCA assessment) and if one of the following occurs:
A positive history of recurrent angina pectoris, presumably related to the target vessel;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);
A target vessel revascularization (TVR) with a diameter stenosis ≥ 70% even in the absence of the above-mentioned ischemic signs or symptoms.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>Target vessel failure (TVF) is defined as the composite endpoint of:
cardiac death,
target-vessel myocardial infarction (Q wave or non-Q wave), and
clinically indicated target vessel revascularization</description>
        <time_frame>240 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>Target vessel failure (TVF) is defined as the composite endpoint of:
cardiac death,
target-vessel myocardial infarction (Q wave or non-Q wave), and
clinically indicated target vessel revascularization</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Failure (TLF)</title>
        <description>Target lesion failure (TLF) is defined as the composite endpoint of:
cardiac death,
target-lesion myocardial infarction (Q wave or non-Q wave), and
clinically indicated target lesion revascularization</description>
        <time_frame>240 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure (TLF)</title>
          <description>Target lesion failure (TLF) is defined as the composite endpoint of:
cardiac death,
target-lesion myocardial infarction (Q wave or non-Q wave), and
clinically indicated target lesion revascularization</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>The presence of an intracoronary thrombus that originates in the stent or in the segments 5 mm proximal or distal to the stent post-procedure</description>
        <time_frame>240 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>The presence of an intracoronary thrombus that originates in the stent or in the segments 5 mm proximal or distal to the stent post-procedure</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Evaluation: In-stent Binary Restenosis</title>
        <description>Binary Restenosis is defined as ≥50% luminal narrowing at follow-up angiography.</description>
        <time_frame>4 months, 6 months, 8 months</time_frame>
        <population>Patients evaluated at 4(n=10), 6(n=10) and 8(n=10) months.</population>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Evaluation: In-stent Binary Restenosis</title>
          <description>Binary Restenosis is defined as ≥50% luminal narrowing at follow-up angiography.</description>
          <population>Patients evaluated at 4(n=10), 6(n=10) and 8(n=10) months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Evaluation: In-stent Binary Restenosis</title>
        <description>Binary Restenosis is defined as ≥50% luminal narrowing at follow-up angiography.</description>
        <time_frame>18 months</time_frame>
        <population>Population includes participants from whom data was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Evaluation: In-stent Binary Restenosis</title>
          <description>Binary Restenosis is defined as ≥50% luminal narrowing at follow-up angiography.</description>
          <population>Population includes participants from whom data was collected.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intravascular Ultrasound (IVUS) Evaluation: % Neointimal Volume Obstruction</title>
        <description>% neointimal volume obstruction is defined as the neointimal volume divided by stent volume.</description>
        <time_frame>8 months</time_frame>
        <population>Patients evaluated at 4(n=10), 6(n=10) and 8(n=10) months. Only 25/30 patients had evaluable IVUS data.</population>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Intravascular Ultrasound (IVUS) Evaluation: % Neointimal Volume Obstruction</title>
          <description>% neointimal volume obstruction is defined as the neointimal volume divided by stent volume.</description>
          <population>Patients evaluated at 4(n=10), 6(n=10) and 8(n=10) months. Only 25/30 patients had evaluable IVUS data.</population>
          <units>percentage of volume obstruction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IVUS Evaluation: % Neointimal Volume Obstruction</title>
        <description>% neointimal volume obstruction is defined as the neointimal volume divided by stent volume.</description>
        <time_frame>18 months</time_frame>
        <population>20 out of 30 participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>IVUS Evaluation: % Neointimal Volume Obstruction</title>
          <description>% neointimal volume obstruction is defined as the neointimal volume divided by stent volume.</description>
          <population>20 out of 30 participants analyzed</population>
          <units>percentage of volume obstruction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Optical Coherence Tomography (OCT) Evaluation: % Stent Strut Uncovered</title>
        <description>% stent strut uncovered is defined as the ratio of uncovered struts to total struts in all cross-sections.</description>
        <time_frame>8 months</time_frame>
        <population>Patients evaluated at 4(n=10), 6(n=10) and 8(n=10) months. Only 9/30 patients had evaluable OCT at the 8 month timeframe.</population>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>Optical Coherence Tomography (OCT) Evaluation: % Stent Strut Uncovered</title>
          <description>% stent strut uncovered is defined as the ratio of uncovered struts to total struts in all cross-sections.</description>
          <population>Patients evaluated at 4(n=10), 6(n=10) and 8(n=10) months. Only 9/30 patients had evaluable OCT at the 8 month timeframe.</population>
          <units>percentage of struts uncovered</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="2.87" lower_limit="0" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OCT Evaluation: % Stent Strut Uncovered</title>
        <description>% stent strut uncovered is defined as the ratio of uncovered struts to total struts in all cross-sections.</description>
        <time_frame>18 M</time_frame>
        <population>27 out of 30 patients analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MiStent SES</title>
            <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
          </group>
        </group_list>
        <measure>
          <title>OCT Evaluation: % Stent Strut Uncovered</title>
          <description>% stent strut uncovered is defined as the ratio of uncovered struts to total struts in all cross-sections.</description>
          <population>27 out of 30 patients analyzed</population>
          <units>percentage of struts uncovered</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Regular investigator assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>MiStent SES</title>
          <description>The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Increase tendency to bruise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dennis Donohoe, MD, Chief Medical Advisor</name_or_title>
      <organization>Micell Technologies</organization>
      <phone>919-313-2102</phone>
      <email>ddonohoeconsult@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

